Common TitleESS40002
Official Title A 96-Week, Randomized, Open-Label, Multicenter Trial to Evaluate the Safety and Tolerability of the Antiretroviral Activity of Stavudine (40 mg BID) Plus Lamivudine (150mg BID) Plus Nelfinavir (1250 mg BID) Versus Abacavir (300 mg BID) Plus Combivir (3TC 150mg/ZDV 300 mg BID) Versus Combivir (3TC 150 mg/ZDV 300 mg BID) Plus Nelfinavir (1250mg BID) in HIV-1 Infected Subjects
Phase Phase IV
ClinicalTrials.gov NCT00005106
Treatments
Nelfinavir
, Nelfinavir
Tradename:ViraceptOther Names:NFVClass:Protease Inhibitors (PI)Abacavir-Lamivudine-Zidovudine
Abacavir-Lamivudine-Zidovudine
Tradename:TrizivirOther Names:ABC-3TC-ZDVClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Categories PharmacologyTreatment-NaiveAdverse Effects
Funding
IndustryGlaxo Wellcome
References
- Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med. 2006;7:85-98.